German translation and validation of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire–IUGA revised (PISQ-IR) by Gerda Trutnovsky et al.
ORIGINAL ARTICLE
German translation and validation of the Pelvic
Organ Prolapse/Incontinence Sexual Questionnaire–IUGA
revised (PISQ-IR)
Gerda Trutnovsky1 & Eva Nagele1 & Daniela Ulrich1 & Thomas Aigmüller1 &
Daniela Dörfler2 & Ingrid Geiss3 & Evi Reinstadler4 & Johannes Angleitner-Flotzinger5 &
Jean-Jacques Ries6 & Vesna Bjelic-Radisic1 &
on behalf of the Austrian Urogynecology Working Group
Received: 18 November 2015 /Accepted: 28 January 2016 /Published online: 16 February 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Introduction and hypothesis Condition-specific sexual ques-
tionnaires are essential for clinical trials and important patient-
reported outcomemeasures. The aim of the study was to trans-
late the Pelvic Organ Prolapse/Incontinence Sexual
Questionnaire–International Urogynecology Association
Revised (PISQ-IR) into German and to clinically validate it
in a German-speaking population.
Methods The translated PISQ-IR was linguistically validated
in two rounds of cognitive interviews. The final instrument
was psychometrically validated in women presenting to
urogynecological clinics with pelvic floor dysfunction. For
analysis of criterion validity, three related self-reported mea-
sures were administered: the Female Sexual Function Index
(FSFI), the Kings Health Questionnaire (KHQ), and the 36-
Item Short Form Health Survey (SF-36). For external validity,
PISQ-IR subscales were compared to the clinical-measures
Pelvic Organ Prolapse Quantification system (POP-Q) stage,
pelvic floor muscle tone, and Oxford Grading Scale.
Descriptive statistics, floor and ceiling effects, internal consis-
tency using Cronbach’s alpha coefficient, and Pearson corre-
lations were calculated for all PISQ-IR subscales.
Results The PISQ-IR was completed by 197 women, out of
whom 66 (33.5 %) considered themselves not sexually active
(NSA) and 131 (66.5 %) as sexually active (SA). Participants’
mean age was 57±12 years; 50%were diagnosed with symp-
tomatic POP, 74 % with urinary incontinence (UI) and 4 %
with anal incontinence (AI). The PISQ-IR subscales were an-
alyzed separately for SA and NSA women with Cronbach’s
alpha coefficients ranging from 0.64 to 0.94. Moderate to high
correlations were observed between PISQ-IR subscales and
related quality of life (QoL) scales and corresponding FSFI
scales.
Conclusion Initial testing of the German PISQ-IR suggests it
is an internally consistent and valid tool for use in clinical
practice and research.
Keywords PISQ-IR . Sexual function . Pelvic floor disorder .
Questionnaire . Validation
Introduction
Sexual health is an integral part of quality of life (QoL) and
may play an important role up to and into to old age [1, 2].
Pelvic floor dysfunction (PFD) increases with age and is likely
to negatively affect sexual activities [3–6]. Urinary (UI) and
fecal (FI) incontinence have been associated with low libido,
dyspareunia, and avoidance of sexual activity for fear of
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losing urine or stool [3, 7–9]. Pelvic organ prolapse (POP)
may cause discomfort, decrease sexual excitement, and influ-
ence a woman’s decision not to be sexually active [3, 10–12].
Evaluation of sexual activity and function should be an in-
tegral part of urogynecologic assessment, since this information
is essential for therapy planning. Comprehensive physician-led
interviews covering different aspects of sexuality are still rare,
and questionnaires are increasingly used for evaluation of fe-
male sexual function. Condition-specific sexual questionnaires
are essential for clinical trials and important patient-reported
outcome measures. Thus, the International Urogynecology
Association (IUGA) developed a new questionnaire for evalu-
ating the impact of PFD on sexual function and activity: the
Pelvic Organ Prolapse/Urinary Incontinence Questionnaire-
IUGA revised (PISQ-IR) [5, 6]. In contrast to previous tools,
this PFD-specific questionnaire addresses sexually active (SA)
women as well as women without a partner and those who
consider themselves not to be sexually active (NSA). The
PISQ-IR was validated in >500 women seeking treatment for
UI and/or anal incontinence (AI) and/or POP in several clinical
sites from across the USA and UK. The questionnaire is based
in a multicultural framework, and translation and validation in
several languages is ongoing or already completed [13, 14].
In German there are currently three validated questionnaires
on sexual function available: the Female Sexual Function
Index (FSFI) [15], the Sexual Activity Questionnaire (SAQ)
[16], and the McCoy Female Sexuality Questionnaire
(MFSQ). However, none of them is PFD-specific, and there
is an urgent need for a valid sexual function scale for use in
urogynecological research. The aim of this study was to trans-
late the PISQ-IR into German and to clinically validate it in a
German-speaking population of women with PFD.
Materials and methods
Original PISQ-IR questionnaire
The validity, reliability, and responsiveness of the original
English-language version of the PISQ-IR was established in
a population of women with PFD [9]. The questionnaire con-
sists of two sections: one for NSA and one for SAwomen and
comprises 12 or 21 items, respectively. The division is based
on the result of the core-branching item 1, where women are
asked to indicate whether they consider themselves to SA or
NSA, with or without a partner. The two sections are analyzed
independently, each consisting of two domains and different
subscales. The NSA section contains the following four sub-
scales: condition-specific reasons for sexual inactivity (NSA-
CS), partner- and personal-interest-related reasons for sexual
inactivity (NSA-PR), global rating of sexual quality (NSA-
GQ), and condition impact (NSA-CI). The SA section con-
tains the following six subscales: sexual arousal and orgasm
(SA-AO), partner-related issues (SA-PR), condition-specific
issues (SA-CS), global quality (SA-GQ), sexual desire (SA-
D), and a condition-specific subscale (SA-CS). All subscales
are analyzed separately, and calculation of a summary score is
not recommended [17]. In the NSA group, a higher score
indicates greater negative impact of urogynecological symp-
toms, whereas for SA women, a higher score indicates less
impact and better sexual function.
Translation and linguistic validation
Translation into German was undertaken by a German-
speaking Austrian-native translator with profound English
language skills and a broad knowledge of questionnaire de-
velopment and sexual issues. Special consideration was given
to avoid offending or misleading phrases and ensure cultural
acceptance without loosing the particular context and intent of
each question.
In a subsequent community review process, the translated
instrument was trialed for it is consistency and acceptance.
During ten cognitive interviews with women with PFD, the
intent and wording of each item was discussed. In a one-on-
one session, taking between 30 and 60 min, women were
probed about their initial reactions, their understanding of
the content, and whether there was any alternative wording
they would find easier to understand or relate to. Based on the
results of the cognitive interviews, the instrument was revised
and subjected to a second round of ten cognitive interviews.
After finalizing the wording of the German version, each
question was translated back into English by an independent
Austrian-native English-speaking translator. The completed
Forward-Translation/Back-Translation form was reviewed
by the IUGA PISQ-R working group.
Psychometric validation
For clinical validation, the German language version question-
naire was then administered to women presenting to urogyne-
cology clinics. According to the PISQ-IRTranslation Protocol
enrolment of 220 women—120 SA and 100 NSA —was
planned. Inclusion criteria were a diagnosis of UI and/or AI
and/or POP and sufficient German language skills. Exclusion
criteria were diagnosis of vulvodynia, painful bladder syn-
drome, or chronic pelvic pain. A convenience sample of wom-
en meeting these criteria was asked to participate and was
enrolled in the validation study. Informed consent was collect-
ed from all participants, and ethics approval was obtained
from the university and local ethics committees.
A standardized interview included current symptoms, ob-
stetric and gynecologic history, and past and ongoing
urogynecologic therapies. A physical examination was per-
formed to stage POP according to the POP-Q classification
[18]. Clinical assessment of pelvic floor muscles was
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performed by vaginal digital palpation for assessment of mus-
cle tone and contractility. The six-point Oxford Grading Scale
was used to rate contractility from 0 (no muscular action) to 5
(strong squeeze and lift) [19]. For analysis of criterion validity,
three related and previously validated self-reported measures
were administered in addition to the PISQ-IR. The FSFI is a
19-item questionnaire for assessment of several aspects of
sexual functioning in a general population and contains the
following six subscales: desire, arousal, lubrication, orgasm,
satisfaction, and pain, with higher scores indicating better sex-
ual function [15]. The Kings Health Questionnaire (KHQ) is a
32-item, condition-specific instrument to assess quality of life
(QoL) in women with UI and contains nine subscales: general
health perception, incontinence impact, role limitations, phys-
ical limitations, social limitations, personal relationship, emo-
tional problems, sleep and energy disturbances, and symptom
severity, with higher values indicating worse QoL [20]. The
36-Item Short Form Health Survey (SF-36) is generic and
widely used to assess perceived health state and QoL compris-
ing eight health domains: Physical Functioning, Emotional-
role Functioning (role limitations due to emotional problems),
Social Functioning, Bodily Pain, Mental Health (psychologi-
cal distress and well-being), Physical-role Functioning (role
limitations due to physical health), Vitality (energy and fa-
tigue), and General Health, with higher scores indicating bet-
ter QoL [21]. Participating women were handed the survey
packet comprising all four questionnaires and asked to return
the completed forms in a prepaid envelope via mail.
Statistical analysis
Differences in clinical characteristics and questionnaire data
between NSA and SA women were assessed with Student t
tests. Descriptive statistics and floor and ceiling effects, i.e.
percentages of patients with the lowest and highest possible
scores, were calculated for all PISQ-IR subscales. Internal
consistency was assessed with the use of Cronbach’s alpha
coefficient. Subscales were scored when at least half of the
items were answered; transformed summation, i.e. transfor-
mation of all items to a 0–100 range, was applied.
According to the recommendation of the PISQ-IR study
group, imputation of missing values was not performed [17].
To assess criterion validity, PISQ-IR subscales were compared
with the reference questionnaires FSFI (for SAwomen only),
KHQ (for women with diagnosed UI only), and SF-36. For
external validity, PISQ-IR subscales were compared with
clinical-measures POP-Q stage, Oxford Grading Scale and
pelvic floor muscle tone. For analysis, Pearson correlations
or Spearman’s rank-sum correlations were use, with values
of 0.3–0.5 indicating weak, >0.5–0.7 indicating moderate,
and >0.7 indicating strong correlation. A p value <0.05 was
regarded as significant. Scale responsiveness and test–retest
reliability were established for the original questionnaire and
were not assessed in this study.
Results
PISQ-IR translation
During the translation process and cognitive interviews, sev-
eral challenging key phrases, i.e. Bbulging in the vagina^, or
Bsexually inferior^ were identified and extensively discussed
before the most appropriate wording was found. For the core-
branching question about sexual activity, the phrase Bsexually
active with or without sexual intercourse^ was added to the
phrase Bwith or without a partner .^ The number and contents
of items remained unchanged, but a short introduction
explaining the rationale and content of the questionnaire was
added. The 20 women who participated in the cognitive inter-
views were all diagnosed with at least one PFD—60 % with
UI and 55 % with POP–and had a mean age of 61.4 years
[standard deviation (SD 8.8)]. The final German version was
well received and understood. However, at the end of the
validation, process a nonresponse rate of up to 55 % was
observed for some items, and this seemed to be due to the
differing answering formats. As a consequence, the answering
format of two questions—Q4 for NSA and Q19 for SAwom-
en—was modified to fit the other answering formats (see
Appendix 1).
PISQ-IR validation
Five urogynecological centers throughout Austria and one
Swiss center participated in the validation process. A total of
215 women returned the survey packets (four questionnaires);
the PISQ-IR was completed by 197 (92 %), and the validation
analysis was restricted to these women. According to the an-
swer of the PISQ-IR core-branching item 1, 66 women
(33.5 %) considered themselves NSA and 131 (66.5 %) SA.
The clinical characteristics of the study population are shown
in Table 1. SA women were on average 7 years younger, but
otherwise, there were no significant differences between the
two groups. Overall, the majority of women (70 %) were
postmenopausal, 50 % were diagnosed with symptomatic
POP, 74 % with UI, and 4 % with AI. Results of the SF-36
and KHQ subscales (Table 1) indicate that SA women had
better general and condition-specific QoL than NSAwomen.
However, differences did not reach statistical significance,
except for the two KHQ subscales Brole limitations^ and
Bsleep and energy disturbances.^
The PISQ-IR results were analyzed separately for SA and
NSAwomen, as recommended in the original publication [6].
Item nonresponse rates ranged from 9 % to 55 % in the NSA
group (median 30 %; 20/66) and from 2 % to 40 % in the SA
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Table 1 Clinical characteristics
and quality of life (QoL) ques-
tionnaire results of the study
population
Sexually inactive Sexually active Total
N= 66 N= 131 N= 197
Age (mean ± SD) 62 (12)* 55 (12)* 57 (12)
BMI (mean ± SD) 27.5 ( 5.5) 26.8 (4.7) 27.0 (5.0)
Parity (mean ± SD) 2.0 (1.1) 2.3 (1.3) 2.2 (1.2)
Postmenopausal 82 % 62 % 70 %
Past surgical history N = 64 N = 118 N = 182
Hysterectomy 30 % 26 % 28 %
Prior prolapse surgery 9 % 15 % 14 %
Prior incontinence surgery 22 % 13 % 16 %
Clinical diagnosis N = 63 N = 118 N = 181
Symptomatic POP 46 % 52 % 50 %
Stress UI 13 % 30 % 24 %
Urge UI 33 % 13 % 20 %
Mixed UI 32 % 30 % 30 %
Anal Incontinence 3 % 5 % 4 %
POP-Q stage N = 44 N = 59 N = 103
Stage 0 and I 34 % 36 % 35 %
Stage II 46 % 39 % 42 %
Stage III and IV 21 % 25 % 23 %
Oxford Grading Scale N = 58 N = 106 N = 164
No contraction/flicker 10 % 15 % 13 %
Weak 55 % 39 % 46 %
Moderate 26 % 26 % 26 %
Good/strong 9 % 21 % 16 %
Pelvic floor muscles N = 58 N = 105 N = 163
Normal 72 % 65 % 68 %
Overactive 2 % 2 % 2 %
Underactive 22 % 30 % 27 %
Nonfunctioning 3 % 4 % 4 %
SF-36 scalesa N = 65 N = 123 N = 188
Physical functioning 66.8 (24.5) 70.7 (23.6) 69.3(23.9)
Role physical 58.3 (42.4) 66.6 (39.9) 63.8 (40.8)
Bodily pain 64.9 (30.2) 68.8 (28.3) 67.5 (28.9)
General health perception 59.6 (19.8) 63.6 (19.5) 62.2 (19.6)
Vitality 48.8 (23.5) 54.7 (19.0) 52.6 (20.8)
Social functioning 72.3 (27.8) 79.0 (23.7) 76.7 (25.3)
Role-emotional 63.7 (45.9) 72.7 (42.5) 69.8 (43.7)
Mental health 65.3 (22.1) 66.6 (20.2) 66.2 (20.8)
KHQ scalesb N = 50 N = 91 N = 141
General health perception 40.5 (20.1) 39.0 (23.6) 39.5 (22.4)
Incontinence impact 73.3 (30.1) 64.4 (29.9) 67.6 (30.2)
Role limitations 64.2 (31.5)* 52.8 (31.9)* 56.8 (32.1)
Physical limitations 61.6 (34.1) 50.5 (30.3) 54.4 (31.9)
Social limitations 30.8 (30.1) 21.4 (24.9) 24.7 (27.1)
Personal relationship 46.2 (36.1) 29.3 (31.1) 31.6 (32.1)
Emotional problems 45.4 (31.4) 42.5 (30.2) 43.5 (30.6)
Sleep and energy disturbances 50.4 (25.9)* 31.4 (27.9)* 38.1 (28.6)
Symptom severity 69.3 (22.0) 63.9 (27.4) 65.8 (25.7)
Overactive bladder 47.0 (22.2) 45.7 (29.2) 46.1 (26.9)
Data is given in percent or mean (standard deviation)
* p < .05;
a Higher scores indicate better quality of life
b Higher scores indicate worse quality of life
1238 Int Urogynecol J (2016) 27:1235–1244
group (median 7 %; 9/131). Table 2 shows mean values, in-
ternal consistency reliability, and floor and ceiling effects of
the PISQ-IR subscales. Cronbach’s alpha coefficients ranged
from 0.64 to 0.94, with two subscales (NSA- CS, and SA-D)
being below the acceptable level of 0.7; all other scales indi-
cated a good level of internal consistency.
Ceiling effects were seen for the NSA-PR subscale, with
51 % of women reporting the worst possible score. This indi-
cates that having no partner and having no interest were com-
mon reasons for sexual inactivity. Floor effects were found in
the NSA-CI, indicating that for 40 % of NSA women, PFD
had no impact. Moderate ceiling effects were seen in the sub-
scales SA-CI and SA-CS, where 29 and 30 % of women,
respectively, reported the best possible score. This indicates
that in those women urogynecological problems had no im-
pact on their sexuality. Table 3 shows the analysis of criterion
validity for NSAwomen. Significant correlations in the antic-
ipated directions were observed between the subscales NSA-
CS and NSA-CI and most SF-36 and KHQ subscales.
Correlations ranged between 0.34 and 0.93 and were strongest
for the SF-36 domain Bemotional-role functioning^ and the
KHQ scale Bpersonal relationship.^ There were no significant
correlations with clinical measures, except between body
mass index (BMI) and NSA-PR.
Criterion validity analysis for SAwomen is shown in Table
4. Moderate correlations in the anticipated direction were seen
between PISQ-IR subscales, especially SA-OA, SA-CS, and
SA-CI, and most SF-36 and KHQ subscales, indicating that
both general and condition-specific QoL are positively related
to better sexual functioning.Moderate to high correlations were
observed between corresponding scales of the FSFI and PISQ-
IR—i.e., desire, arousal, orgasm, satisfaction/global quality—
confirming good criterion validity. High pelvic floor muscle
contractility, i.e. Oxford Grading Scale, was positively
correlated with SA-AO. A higher POP-Q stage and lower mus-
cle contractility were correlated with worse SA-CI.
Discussion
The PISQ-IR is a valuable tool for assessing sexual function in
women with PFD, both for clinical practice and for research.
The present German translation and clinical validation dem-
onstrates sound psychometric properties and will allow its use
in the German-speaking urogynecological population. The
qualitative linguistic validation showed a high level of accep-
tance, and only a few adaptations were necessary. However,
during the clinical validation process, a substantial nonre-
sponse rate, especially in the NSA group, was observed for
selected single items. This seemed to be due to the varying
answering format of these items, and as a consequence, the
format was adapted. The high number of missing values may
also be explained by the fact that four different questionnaires
were used: the PISQ-IR, FSFI, SF-36, and KHQ. However,
their combined use allowed us to examine the relationship
between various general and condition-specific QoL domains
and sexual function in NSA and SA women. Several strong
correlations between related subscales were observed,
confirming the good criterion validity of the newly translated
PISQ-IR. Internal validity was acceptable, with Cronbach’s
alpha values >0.70, except for NSA-CS and SA-D. Overall,
scale correlations and internal validity were comparable with
the original PISQ-IR validation [6].
A strength of the study was the sufficiently large sample
size and correlation with clinical parameters, i.e., pelvic mus-
cular function. One advantage of the PISQ-IR is the possibility
to evaluate SA as well as NSA women. While in our study
population having no partner or having a lack of interest was






Scale No. of items Mean± SD Cronbach’s alpha Floor Ceiling
NSA (N=66)
Condition-specific (NSA-CS) 3 32.87 ± 30.64 0.64 28 % 6 %
Partner-related (NSA-PR) 2 75.99 ± 30.68 n.a. 5 % 51 %
Global quality (NSA-GQ) 4 38.23 ± 33.97 0.94 32 % 6 %
Condition impact (NSA-CI) 3 34.61 ± 34.21 0.87 40 % 4 %
SA (N= 131)
Arousal/orgasm (SA-AO) 3 57.78 ± 22.15 0.81 2 % 2 %
Partner-related (SA-PR) 3 75.07 ± 20.28 0.80 1 % 20 %
Condition-specific (SA-CS) 3 78.17 ± 23.02 0.70 1 % 29 %
Global quality (SA-GQ) 4 67.67 ± 24.77 0.91 3 % 18 %
Condition impact (SA-CI) 4 67.93 ± 29.60 0.87 1 % 30 %
Desire (SA-D) 3 49.05 ± 18.77 0.69 4 % 2 %
Mean scores are transformed to a 0–100 range. In the NSA group, a higher value indicates a greater negative
impact. For SAwomen, a higher value indicates less impact and better sexual function
NSA nonsexually active, SA sexually active, n.a. not assessed because <3 items
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the most common reason for sexual inactivity; only 40 %
reported that PFD had no negative impact at all. Similarly, in
the SA group, more than two thirds indicated that
urogynecological symptoms at least somehow negatively
effected their sexuality. This confirms previous studies, which
found that POP and UI commonly impact on women’s sexu-
ality and are likely reasons for sexual inactivity [3, 10–12].
Our results are limited by the fact that we did not evaluate
test–retest reliability and scale responsiveness, which were
established in the original publication. The relatively high
floor and ceiling effects in the NSA group imply that some
actual variation in patient data may not be reflected. Only a
few women with AI were involved in the validation process,
and future research will need to test the validity of the German
PISQ-IR in this population.
Conclusion
This study confirms that sexual function is commonly affected
by urogynecological symptoms and should be assessed in
womenwith PFD. TheGerman PISQ-IR is a reliable and valid
Table 3 Sexually inactive (NSA) Pelvic Organ Prolapse/Incontinence Sexual Questionnaire–International Urogynecology Association Revised
(PISQ-IR) scale correlations with 36-Item Short Form Health Survey (SF-36), Kings Health Questionnaire (KHQ), and clinical measures









NSA-CS NSA-PR NSA-GQ NSA-CI
SF-36 scales a
Physical functioning −0.55** −0.01 −0.17 −0.20
Role-physical −0.45* 0.11 −0.05 −0.17
Bodily pain −0.40* 0.17 0.04 −0.27
General health perception −0.54** 0.07 −0.10 −0.22
Vitality −0.41* 0.21 −0.16 −0.19
Social functioning −0.45** 0.03 −0.18 −0.26
Role-emotional −0.65** 0.13 −0.12 −0.34*
Mental health −0.44** 0.09 −0.18 −0.26
KHQ scales b
General health perception 0.54** −0.11 −0.06 0.10
Incontinence impact 0.49** −0.11 −0.17 0.53**
Role limitations 0.58** −0.01 −0.34* 0.28
Physical limitations 0.46* 0.04 −0.30 0.26
Social limitations 0.55** 0.00 −0.25 0.29
Personal relationship 0.86* −0.21 0.49 0.93**
Emotional problems 0.54** −0.04 −0.11 0.28
Sleep and energy disturbances 0.45* 0.21 −0.18 0.20
Symptom severity 0.59** −0.06 0.06 0.62**
Overactive bladder 0.31 0.28 −0.26 −0.08
Clinical measures
BMI −0.11 −0.40** 0.25 0.24
Pelvic tone (0 = normal, 1 = not normal) 0.08 0.14 −0.12 −0.15
POP-Q 0.09 0.29 −0.13 0.03
Oxford Grading Scale 0.01 −0.13 0.06 0.11
For POP-Q and the Oxford Grading Scale, Spearman’s rank-sum correlations were computed; all other correlations assessed with Pearson correlations
(values >0.50 in bold)
BMI body mass index, POP-Q Pelvic Organ Prolapse Quantification system, QoL quality of life
* p < .05, ** p< .005.
a Higher scores indicate better QoL
b KHQ analysis limited to women with urinary incontinence; higher scores indicate worse QoL
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Table 4 Sexually active- Pelvic Organ Prolapse/Incontinence Sexual
Questionnaire–International Urogynecology Association Revised (PISQ-
IR) scale correlations with 36-Item Short Form Health Survey (SF-36),
Kings Health Questionnaire (KHQ), Female Sexual Function Index
(FSFI), and clinical measures



















SA-AO SA-PR SA-CS SA-GQ SA-CI SA-D
SF-36 scales a
Physical functioning 0.47** 0.10 0.37** 0.38** 0.38** 0.18
Role physical 0.35** 0.09 0.30** 0.27** 0.28** 0.07
Bodily pain 0.35** 0.18 0.41** 0.36** 0.30** 0.12
General health perception 0.29** 0.30** 0.39** 0.25** 0.20* 0.18
Vitality 0.22* 0.14 0.41** 0.31** 0.22* 0.19*
Social functioning 0.24** 0.17 0.49** 0.27** 0.30** 0.07
Role-emotional 0.26** 0.09 0.36** 0.14 0.20* 0.11
Mental health 0.22* 0.33** 0.48** 0.32** 0.28** 0.19*
KHQ scales b
General health perception −0.34** −0.24* −0.50** −0.33** −0.30** −0.30**
Incontinence impact −0.19 −0.21 −0.33** −0.34** −0.36** −0.08
Role limitations −0.26* −0.12 −0.32** −0.28* −0.38** −0.03
Physical limitations −0.13 −0.09 −0.23* −0.16 −0.28** 0.08
Social limitations −0.19 −0.19 −0.46** −0.13 −0.37** 0.09
Personal relationship −0.44** −0.24* −0.52** −0.39** −0.62** −0.01
Emotional problems −0.27* −0.27* −0.37** −0.26* −0.41** 0.02
Sleep and energy
disturbances
−0.23* −0.05 −0.32** −0.17 −0.34** 0.09
Symptom severity −0.22* −0.15 −0.35** −0.20 −0.33** 0.08
Overactive bladder −0.15 0.00 0.00 −0.06 −0.03 0.08
FSFI scales c
Desire 0.42** 0.31** 0.20 0.42** 0.02 0.75**
Arousal 0.61** 0.34** 0.37** 0.44** 0.30** 0.51**
Lubrication 0.46** 0.29** 0.23* 0.35** 0.22* 0.43**
Orgasm 0.61** 0.31** 0.33** 0.45** 0.33** 0.34**
Satisfaction 0.32** 0.38** 0.40** 0.56** 0.34** 0.33**
Pain 0.20 0.19 0.38** 0.42** 0.48** 0.25*
Total score 0.51** 0.35** 0.35** 0.51** 0.34** 0.51**
Clinical measures
BMI −0.11 −0.05 −0.10 −0.03 0.00 −0.01
Pelvic floor tone −0.10 0.03 −0.09 −0.08 −0.11 −0.04
POP-Q −0.13 −0.00 0.26 0.04 −0.34** −0.06
Oxford Grading Scale 0.26** −0.04 0.05 0.09 0.20* 0.13
For POP-Q and the Oxford Grading Scale, Spearman’s rank-sum correlations were computed; all other correlations were assessed with Pearson
correlations (values >0.50 in bold)
BMI body mass index, POP-Q Pelvic Organ Prolapse Quantification system
* p < .05, ** p< .005.
a Higher scores indicate better QoL
b KHQ analysis limited to women with urinary incontinence only, higher scores indicate worse QoL
c Higher scores indicate better sexual function
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tool for use in a German-speaking urogynecological popula-
tion. Future use of this questionnaire will be important to
assess the effect of the adapted format on missing values and
ceiling effects. Future prospective clinical trials should also
confirm the stability and establish the clinical responsiveness
of the German PISQ-IR.
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Appendix 1
PISQ-R Fragebogen Erkrankungen des weiblichen Genitals und
der Harnblase können alle Lebensbereiche betroffener Frauen
beeinflussen- auch die Sexualität. Wir sind daran interessiert zu erfahren,
wie sich die Beschwerden auswirken, bzw. was durch Therapien
verbessert werden kann. Wir würden Sie daher bitten uns einige Fragen
über Ihr derzeitiges Sexualleben zu beantworten - alle Antworten werden
natürlich vertraulich behandelt!
F1 Was im Folgenden beschreibt Sie am besten:
Abschnitt sexuell nicht aktiv F2 Im Folgenden sind Gründe
angeführt, warum Sie nicht sexuell aktiv sind. Geben Sie bitte an
inwieweit die Gründe für Sie zutreffen.
F3 Vermeiden Sie sexuelle Aktivität auch aus Angst vor Harn oder
Stuhlverlust bzw. aufgrund eines Senkungsgefühls in der Scheide?
1 □ Überhaupt nicht
2 □ Ein bisschen
3 □ Etwas
4 □ Sehr
F4 Wie sehr stimmen Sie den folgenden Aussagen zu (nicht zu)
F5 Wie sehr stimmen Sie den folgenden Aussagen zu (nicht zu)
F6 Wie sehr stört es Sie, dass Sie nicht sexuell aktiv sind?
1 □ Überhaupt nicht
2 □ Ein bisschen
3 □ Etwas
4 □ Sehr
Ende des Abschnittes Sexuell nicht aktiv
Abschnitt sexuell aktiv F7 Wie oft fühlen Sie sich während





5 □ Fast immer





Gehen Sie zu F2 – Abschnitt nicht
sexuell aktiv





















a Kein Partner □1 □2 □3 □4
b Kein Interesse □1 □2 □3 □4
c Wegen Harn- oder
Stuhlverlust oder
wegen Senkung
□1 □2 □3 □4
d Wegen meiner anderen
Gesundheits-probleme
□1 □2 □3 □4
















































□1 □2 □3 □4




□1 □2 □3 □4




□1 □2 □3 □4
nie selten manchmal oft Fast immer
a. Befriedigung □1 □2 □3 □4 □5
c. Scham □1 □2 □3 □4 □5
d. Angst □1 □2 □3 □4 □5
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5 □ Fast immer
F10 Verglichen mit sexuellen Höhepunkten, die Sie in der
Vergangenheit hatten, wie intensiv sind Ihre sexuellen Höhepunkte jetzt?
1 □ Viel weniger intensiv
2 □Weniger intensiv
3 □ Gleich intensiv
4 □ Intensiver
5 □ Viel intensiver
F11 Wie oft haben Sie beim Geschlechtsverkehr Schmerzen? (Wenn
Sie keinen Geschlechtsverkehr haben kreuzen Sie dieses Kästchen □ an






F12 Haben Sie einen Sexualpartner/eine Sexualpartnerin?
1 □ Ja➔Weiter mit F 13
2 □ Nein➔Weiter mit F15
F13 Wie oft hat Ihr Partner/Ihre Partnerin ein Problem (Mangel an





4 □ Fast nie/selten
F14 Würden Sie sagen, dass Ihr Partner/Ihre Partnerin im
Allgemeinen einen positiven oder negativen Einfluss auf folgenden
Bereich hat?







F16 Wie häufig haben Sie ein sexuelles Verlangen (das kann Wunsch





4 □Weniger als einmal im Monat
5 □ Nie
F17 Wie würden Sie den Grad Ihres sexuellen Bedürfnisses oder
Interesses beurteilen?




5 □ Sehr niedrig oder gar nicht vorhanden
F18 Vermeiden Sie sexuelle Aktivität aus Angst vor Harn oder
Stuhlverlust bzw. aufgrund eines Senkungsgefühls in der Scheide?




F 19 Wie sehr stimmen Sie den folgenden Aussagen zu (nicht zu)?














a. Auf Ihre sexuelle Lust □1 □2 □3 □4
b. Auf die Häufigkeit Ihrer
sexuellen Aktivität































□1 □2 □3 □4 □5






















□1 □2 □3 □4




□1 □2 □3 □4
c. Mein Sexualleben ist mir
unangenehm
□1 □2 □3 □4




□1 □2 □3 □4
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